|| M.A. Duggan, W.F. Anderson, S. Altekruse, L. Penberthy, M.E. Sherman, The Surveillance, Epidemiology, and End Results (SEER) Program and Pathology: Toward Strengthening the Critical Relationship, Am. J. Surg. Pathol., 40 (2016) e94–e102.|
 P.M. de Groot, C.C. Wu, B.W. Carter, R.F. Munden, The epidemiology of lung cancer, Transl Lung Cancer Res, 7 (2018) 220–233.
 J.S. Chang, L.-T. Chen, Y.-S. Shan, S.-F. Lin, S.-Y. Hsiao, C.-R. Tsai, S.-J. Yu, H.-J. Tsai, Comprehensive Analysis of the Incidence and Survival Patterns of Lung Cancer by Histologies, Including Rare Subtypes, in the Era of Molecular Medicine and Targeted Therapy: A Nation-Wide Cancer Registry-Based Study From Taiwan, Medicine , 94 (2015) e969.
 B.-Y. Wang, J.-Y. Huang, C.-Y. Cheng, C.-H. Lin, J.-L. Ko, Y.-P. Liaw, Lung cancer and prognosis in taiwan: a population-based cancer registry, J. Thorac. Oncol., 8 (2013) 1128–1135.
 N. Riggi, M. Aguet, I. Stamenkovic, Cancer Metastasis: A Reappraisal of Its Underlying Mechanisms and Their Relevance to Treatment, Annu. Rev. Pathol., 13 (2018) 117–140.
 S. Valastyan, R.A. Weinberg, Tumor metastasis: molecular insights and evolving paradigms, Cell, 147 (2011) 275–292.
 Y.-N. Kim, K.H. Koo, J.Y. Sung, U.-J. Yun, H. Kim, Anoikis resistance: an essential prerequisite for tumor metastasis, Int. J. Cell Biol., 2012 (2012) 306879.
 M.L. Taddei, E. Giannoni, T. Fiaschi, P. Chiarugi, Anoikis: an emerging hallmark in health and diseases, J. Pathol., 226 (2012) 380–393.
 N.M. Fofaria, S.K. Srivastava, STAT3 induces anoikis resistance, promotes cell invasion and metastatic potential in pancreatic cancer cells, Carcinogenesis, 36 (2015) 142–150.
 P. Zhang, Y. Song, Y. Sun, X. Li, L. Chen, L. Yang, Y. Xing, AMPK/GSK3β/β-catenin cascade-triggered overexpression of CEMIP promotes migration and invasion in anoikis-resistant prostate cancer cells by enhancing metabolic reprogramming, FASEB J., (2018) fj201701078R.
 Y.-L. Tai, L.-C. Chen, T.-L. Shen, Emerging roles of focal adhesion kinase in cancer, Biomed Res. Int., 2015 (2015) 690690.
 S.M. Frisch, K. Vuori, E. Ruoslahti, P.Y. Chan-Hui, Control of adhesion-dependent cell survival by focal adhesion kinase, J. Cell Biol., 134 (1996) 793–799.
 E. Pachmayr, C. Treese, U. Stein, Underlying Mechanisms for Distant Metastasis - Molecular Biology, Visc Med, 33 (2017) 11–20.
 N.L. Collins, M.J. Reginato, J.K. Paulus, D.C. Sgroi, J. Labaer, J.S. Brugge, G1/S cell cycle arrest provides anoikis resistance through Erk-mediated Bim suppression, Mol. Cell. Biol., 25 (2005) 5282–5291.
 V.M. Golubovskaya, Focal adhesion kinase as a cancer therapy target, Anticancer Agents Med. Chem., 10 (2010) 735–741.
 M. Kohno, J. Pouyssegur, Targeting the ERK signaling pathway in cancer therapy, Ann. Med., 38 (2006) 200–211.
 M.E. Roh, M. Cosgrove, K. Gorski, I.S. Hitchcock, Off-targets effects underlie the inhibitory effect of FAK inhibitors on platelet activation: studies using Fak-deficient mice, J. Thromb. Haemost., 11 (2013) 1776–1778.
 M. Donovan, B. Olofsson, A.L. Gustafson, L. Dencker, U. Eriksson, The cellular retinoic acid binding proteins, J. Steroid Biochem. Mol. Biol., 53 (1995) 459–465.
 Y. Kainov, I. Favorskaya, V. Delektorskaya, G. Chemeris, A. Komelkov, A. Zhuravskaya, L. Trukhanova, E. Zueva, B. Tavitian, N. Dyakova, I. Zborovskaya, E. Tchevkina, CRABP1 provides high malignancy of transformed mesenchymal cells and contributes to the pathogenesis of mesenchymal and neuroendocrine tumors, Cell Cycle, 13 (2014) 1530–1539.
 R.-Z. Liu, E. Garcia, D.D. Glubrecht, H.Y. Poon, J.R. Mackey, R. Godbout, CRABP1 is associated with a poor prognosis in breast cancer: adding to the complexity of breast cancer cell response to retinoic acid, Mol. Cancer, 14 (2015) 129.
 S.-S. Han, W.J. Kim, Y. Hong, S.-H. Hong, S.-J. Lee, D.R. Ryu, W. Lee, Y.H. Cho, S. Lee, Y.-J. Ryu, J.Y. Won, H. Rhee, J.H. Park, S.J. Jang, J.S. Lee, C.-M. Choi, J.C. Lee, S.D. Lee, Y.-M. Oh, RNA sequencing identifies novel markers of non-small cell lung cancer, Lung Cancer, 84 (2014) 229–235.
 S.G. Codreanu, M.D. Hoeksema, R.J.C. Slebos, L.J. Zimmerman, S.M.J. Rahman, M. Li, S.-C. Chen, H. Chen, R. Eisenberg, D.C. Liebler, P.P. Massion, Identification of Proteomic Features To Distinguish Benign Pulmonary Nodules from Lung Adenocarcinoma, J. Proteome Res., 16 (2017) 3266–3276.
 Y. Zhang, H. Wang, J. Wang, L. Bao, L. Wang, J. Huo, X. Wang, Global analysis of chromosome 1 genes among patients with lung adenocarcinoma, squamous carcinoma, large-cell carcinoma, small-cell carcinoma, or non-cancer, Cancer Metastasis Rev., 34 (2015) 249–264.
 F. Bolognani, A.-I. Gallani, L. Sokol, D.S. Baskin, N. Meisner-Kober, mRNA stability alterations mediated by HuR are necessary to sustain the fast growth of glioma cells, J. Neurooncol., 106 (2012) 531–542.
 N.-C. Meisner, W. Filipowicz, Properties of the Regulatory RNA-Binding Protein HuR and its Role in Controlling miRNA Repression, Adv. Exp. Med. Biol., 700 (2011) 106–123.
 W. Yan, Y. Zhang, J. Zhang, S.-J. Cho, X. Chen, HuR is necessary for mammary epithelial cell proliferation and polarity at least in part via ΔNp63, PLoS One, 7 (2012) e45336.
 J. Wang, Y. Guo, H. Chu, Y. Guan, J. Bi, B. Wang, Multiple functions of the RNA-binding protein HuR in cancer progression, treatment responses and prognosis, Int. J. Mol. Sci., 14 (2013) 10015–10041.
 J. Wang, W. Zhao, Y. Guo, B. Zhang, Q. Xie, D. Xiang, J. Gao, B. Wang, Z. Chen, The expression of RNA-binding protein HuR in non-small cell lung cancer correlates with vascular endothelial growth factor-C expression and lymph node metastasis, Oncology, 76 (2009) 420–429.
 R. Muralidharan, J. Panneerselvam, A. Chen, Y.D. Zhao, A. Munshi, R. Ramesh, HuR-targeted nanotherapy in combination with AMD3100 suppresses CXCR4 expression, cell growth, migration and invasion in lung cancer, Cancer Gene Ther., 22 (2015) 581–590.
 M. Heinonen, A. Hemmes, K. Salmenkivi, K. Abdelmohsen, S.-T. Vilén, M. Laakso, M. Leidenius, T. Salo, S. Hautaniemi, M. Gorospe, P. Heikkilä, C. Haglund, A. Ristimäki, Role of RNA binding protein HuR in ductal carcinoma in situ of the breast, J. Pathol., 224 (2011) 529–539.
 A.C. Vreeland, L. Levi, W. Zhang, D.C. Berry, N. Noy, Cellular retinoic acid-binding protein 2 inhibits tumor growth by two distinct mechanisms, J. Biol. Chem., 289 (2014) 34065–34073.
 A.C. Vreeland, S. Yu, L. Levi, D. de Barros Rossetto, N. Noy, Transcript stabilization by the RNA-binding protein HuR is regulated by cellular retinoic acid-binding protein 2, Mol. Cell. Biol., 34 (2014) 2135–2146.
 D.W. Laird, Life cycle of connexins in health and disease, Biochem. J, 394 (2006) 527–543.
 J.L. Esseltine, D.W. Laird, Next-Generation Connexin and Pannexin Cell Biology, Trends Cell Biol., (2016).
 S. Boitano, E.R. Dirksen, W.H. Evans, Sequence-specific antibodies to connexins block intercellular calcium signaling through gap junctions, Cell Calcium, 23 (1998) 1–9.
 M. Sanson, V. Marcaud, E. Robin, C. Valéry, F. Sturtz, B. Zalc, Connexin 43-mediated bystander effect in two rat glioma cell models, Cancer Gene Ther., 9 (2002) 149–155.
 A. Gupta, H. Anderson, A.M. Buo, M.C. Moorer, M. Ren, J.P. Stains, Communication of cAMP by connexin43 gap junctions regulates osteoblast signaling and gene expression, Cell. Signal., 28 (2016) 1048–1057.
 L. Garcia-Rodríguez, S. Pérez-Torras, M. Carrió, A. Cascante, I. García-Ribas, A. Mazo, C. Fillat, Connexin-26 is a key factor mediating gemcitabine bystander effect, Mol. Cancer Ther., 10 (2011) 505–517.
 H. Goodall, B. Maro, Major loss of junctional coupling during mitosis in early mouse embryos, J. Cell Biol., 102 (1986) 568–575.
 L.S. Stein, J. Boonstra, R.C. Burghardt, Reduced cell-cell communication between mitotic and nonmitotic coupled cells, Exp. Cell Res., 198 (1992) 1–7.
 M. Vinken, T. Vanhaecke, P. Papeleu, S. Snykers, T. Henkens, V. Rogiers, Connexins and their channels in cell growth and cell death, Cell. Signal., 18 (2006) 592–600.
 H.A. Coller, Is cancer a metabolic disease?, Am. J. Pathol., 184 (2014) 4–17.
 T. Aasen, M. Mesnil, C.C. Naus, P.D. Lampe, D.W. Laird, Gap junctions and cancer: communicating for 50 years, Nat. Rev. Cancer, 16 (2016) 775–788.
 D. Banerjee, Connexin’s Connection in Breast Cancer Growth and Progression, Int. J. Cell Biol., 2016 (2016) 9025905.
 S.L. Phillips, C.B. Williams, J.N. Zambrano, C.J. Williams, E.S. Yeh, Connexin 43 in the development and progression of breast cancer: What’s the connection? (Review), Int. J. Oncol., 51 (2017) 1005–1013.
 L. Kanczuga-Koda, S. Sulkowski, A. Lenczewski, M. Koda, A. Wincewicz, M. Baltaziak, M. Sulkowska, Increased expression of connexins 26 and 43 in lymph node metastases of breast cancer, J. Clin. Pathol., 59 (2006) 429–433.
 B. Tang, Z.-H. Peng, P.-W. Yu, G. Yu, F. Qian, Expression and significance of Cx43 and E-cadherin in gastric cancer and metastatic lymph nodes, Med. Oncol., 28 (2011) 502–508.
 Y.W. Zhang, I. Morita, M. Ikeda, K.W. Ma, S. Murota, Connexin43 suppresses proliferation of osteosarcoma U2OS cells through post-transcriptional regulation of p27, Oncogene, 20 (2001) 4138–4149.
 S. Sirnes, J. Bruun, M. Kolberg, A. Kjenseth, G.E. Lind, A. Svindland, A. Brech, A. Nesbakken, R.A. Lothe, E. Leithe, E. Rivedal, Connexin43 acts as a colorectal cancer tumor suppressor and predicts disease outcome, Int. J. Cancer, 131 (2012) 570–581.
 S.R. Polusani, E.A. Kalmykov, A. Chandrasekhar, S.N. Zucker, B.J. Nicholson, Cell coupling mediated by connexin 26 selectively contributes to reduced adhesivity and increased migration, J. Cell Sci., 129 (2016) 4399–4410.
 M.K. Elzarrad, A. Haroon, K. Willecke, R. Dobrowolski, M.N. Gillespie, A.-B. Al-Mehdi, Connexin-43 upregulation in micrometastases and tumor vasculature and its role in tumor cell attachment to pulmonary endothelium, BMC Med., 6 (2008) 20.
 K. Stoletov, J. Strnadel, E. Zardouzian, M. Momiyama, F.D. Park, J.A. Kelber, D.P. Pizzo, R. Hoffman, S.R. VandenBerg, R.L. Klemke, Role of connexins in metastatic breast cancer and melanoma brain colonization, J. Cell Sci., 126 (2013) 904–913.
 C. Lamiche, J. Clarhaut, P.-O. Strale, S. Crespin, N. Pedretti, F.-X. Bernard, C.C. Naus, V.C. Chen, L.J. Foster, N. Defamie, M. Mesnil, F. Debiais, L. Cronier, The gap junction protein Cx43 is involved in the bone-targeted metastatic behaviour of human prostate cancer cells, Clin. Exp. Metastasis, 29 (2012) 111–122.
 J.H.-C. Lin, T. Takano, M.L. Cotrina, G. Arcuino, J. Kang, S. Liu, Q. Gao, L. Jiang, F. Li, H. Lichtenberg-Frate, S. Haubrich, K. Willecke, S.A. Goldman, M. Nedergaard, Connexin 43 Enhances the Adhesivity and Mediates the Invasion of Malignant Glioma Cells, J. Neurosci., 22 (2002) 4302–4311.
 W. Zhang, C. Nwagwu, D.M. Le, V.W. Yong, H. Song, W.T. Couldwell, Increased invasive capacity of connexin43-overexpressing malignant glioma cells, J. Neurosurg., 99 (2003) 1039–1046.
 R. Oliveira, C. Christov, J.S. Guillamo, S. de Boüard, S. Palfi, L. Venance, M. Tardy, M. Peschanski, Contribution of gap junctional communication between tumor cells and astroglia to the invasion of the brain parenchyma by human glioblastomas, BMC Cell Biol., 6 (2005) 7.
 B. Tang, Z.-H. Peng, P.-W. Yu, G. Yu, F. Qian, D.-Z. Zeng, Y.-L. Zhao, Y. Shi, Y.-X. Hao, H.-X. Luo, Aberrant expression of Cx43 is associated with the peritoneal metastasis of gastric cancer and Cx43-mediated gap junction enhances gastric cancer cell diapedesis from peritoneal mesothelium, PLoS One, 8 (2013) e74527.
 A.S. Sun, H.C. Yeh, L.H. Wang, Y.P. Huang, H. Maeda, A. Pivazyan, C. Hsu, E.R. Lewis, H.W. Bruckner, T.M. Fasy, Pilot study of a specific dietary supplement in tumor-bearing mice and in stage IIIB and IV non-small cell lung cancer patients, Nutr. Cancer, 39 (2001) 85–95.
 D.W. Bahler, J.G. Frelinger, L.W. Harwell, E.M. Lord, Reduced tumorigenicity of a spontaneous mouse lung carcinoma following H-2 gene transfection, Proc. Natl. Acad. Sci. U. S. A., 84 (1987) 4562–4566.
 K.-T. Lin, J. Gong, C.-F. Li, T.-H. Jang, W.-L. Chen, H.-J. Chen, L.-H. Wang, Vav3-rac1 signaling regulates prostate cancer metastasis with elevated Vav3 expression correlating with prostate cancer progression and posttreatment recurrence, Cancer Res., 72 (2012) 3000–3009.
 Y.-M. Yeh, C.-M. Chuang, K.-C. Chao, L.-H. Wang, MicroRNA-138 suppresses ovarian cancer cell invasion and metastasis by targeting SOX4 and HIF-1α, Int. J. Cancer, 133 (2013) 867–878.
 M. Labelle, R.O. Hynes, The initial hours of metastasis: the importance of cooperative host-tumor cell interactions during hematogenous dissemination, Cancer Discov., 2 (2012) 1091–1099.
 D.R. Rhodes, J. Yu, K. Shanker, N. Deshpande, R. Varambally, D. Ghosh, T. Barrette, A. Pandey, A.M. Chinnaiyan, ONCOMINE: a cancer microarray database and integrated data-mining platform, Neoplasia, 6 (2004) 1–6.
 I.J. Fidler, M.L. Kripke, The challenge of targeting metastasis, Cancer Metastasis Rev., 34 (2015) 635–641.
 H. Uramoto, F. Tanaka, Recurrence after surgery in patients with NSCLC, Transl Lung Cancer Res, 3 (2014) 242–249.
 B. Győrffy, P. Surowiak, J. Budczies, A. Lánczky, Online survival analysis software to assess the prognostic value of biomarkers using transcriptomic data in non-small-cell lung cancer, PLoS One, 8 (2013) e82241.
 J. Li, J. Lin, Y. Luo, M. Kuang, Y. Liu, Multivariate Analysis of Prognostic Biomarkers in Surgically Treated Endometrial Cancer, PLoS One, 10 (2015) e0130640.
 M. Paesmans, Prognostic and predictive factors for lung cancer, Breathe, 9 (2012) 112–121.
 L.E. Coate, T. John, M.-S. Tsao, F.A. Shepherd, Molecular predictive and prognostic markers in non-small-cell lung cancer, Lancet Oncol., 10 (2009) 1001–1010.
 R.-Z. Liu, S. Li, E. Garcia, D.D. Glubrecht, H.Y. Poon, J.C. Easaw, R. Godbout, Association between cytoplasmic CRABP2, altered retinoic acid signaling, and poor prognosis in glioblastoma, Glia, 64 (2016) 963–976.
 S. Fischer-Huchzermeyer, A. Dombrowski, C. Hagel, V.F. Mautner, J. Schittenhelm, A. Harder, The Cellular Retinoic Acid Binding Protein 2 Promotes Survival of Malignant Peripheral Nerve Sheath Tumor Cells, Am. J. Pathol., 187 (2017) 1623–1632.
 K.M.C. Mohammad Sultan, Retinoid Signaling in Cancer and Its Promise for Therapy, J Carcinog Mutagen, (2013).
 N. Mukherjee, P.J. Lager, M.B. Friedersdorf, M.A. Thompson, J.D. Keene, Coordinated posttranscriptional mRNA population dynamics during T-cell activation, Mol. Syst. Biol., 5 (2009) 288.
 Y.-C. Teng, C.-F. Lee, Y.-S. Li, Y.-R. Chen, P.-W. Hsiao, M.-Y. Chan, F.-M. Lin, H.-D. Huang, Y.-T. Chen, Y.-M. Jeng, C.-H. Hsu, Q. Yan, M.-D. Tsai, L.-J. Juan, Histone demethylase RBP2 promotes lung tumorigenesis and cancer metastasis, Cancer Res., 73 (2013) 4711–4721.
 K.K. Ganguly, S. Pal, S. Moulik, A. Chatterjee, Integrins and metastasis, Cell Adh. Migr., 7 (2013) 251–261.
 F.J. Sulzmaier, C. Jean, D.D. Schlaepfer, FAK in cancer: mechanistic findings and clinical applications, Nat. Rev. Cancer, 14 (2014) 598–610.
 T. Miyazaki, H. Kato, M. Nakajima, M. Sohda, Y. Fukai, N. Masuda, R. Manda, M. Fukuchi, K. Tsukada, H. Kuwano, FAK overexpression is correlated with tumour invasiveness and lymph node metastasis in oesophageal squamous cell carcinoma, Br. J. Cancer, 89 (2003) 140–145.
 W. Guo, F.G. Giancotti, Integrin signalling during tumour progression, Nat. Rev. Mol. Cell Biol., 5 (2004) 816–826.
 R. Rosell, L. Crino, K. Danenberg, G. Scagliotti, G. Bepler, M. Taron, V. Alberola, M. Provencio, C. Camps, F. De Marinis, J.J. Sanchez, R. Peñas, Targeted therapy in combination with gemcitabine in non-small cell lung cancer, Semin. Oncol., 30 (2003) 19–25.
 Y. Lin, X. Wang, H. Jin, EGFR-TKI resistance in NSCLC patients: mechanisms and strategies, Am. J. Cancer Res., 4 (2014) 411–435.
 B. Wills, A.F. Cardona, L. Rojas, A. Ruiz-Patiño, O. Arrieta, N. Reguart, H. Carranza, C. Vargas, J. Otero, L. Corrales, C. Martín, M. Cuello, L.E. Pino, C. Rolfo, R. Rosell, Z.L. Zatarain-Barrón, Latin-American Consortium for the Investigation of Lung Cancer (CLICaP), Survival Outcomes According to TIMP1 and EGFR Expression in Heavily Treated Patients with Advanced Non-small Cell Lung Cancer who Received Biweekly Irinotecan Plus Bevacizumab, Anticancer Res., 37 (2017) 6429–6436.
 Y. Xu, M.A. Villalona-Calero, Irinotecan: mechanisms of tumor resistance and novel strategies for modulating its activity, Ann. Oncol., 13 (2002) 1841–1851.
 W.-A. Wang, J. Groenendyk, M. Michalak, Endoplasmic reticulum stress associated responses in cancer, Biochim. Biophys. Acta, 1843 (2014) 2143–2149.
 A.S. Lee, The glucose-regulated proteins: stress induction and clinical applications, Trends Biochem. Sci., 26 (2001) 504–510.
 Y. Xu, Z. Chen, G. Zhang, Y. Xi, R. Sun, X. Wang, W. Wang, F. Chai, X. Li, HSP90B1 overexpression predicts poor prognosis in NSCLC patients, Tumour Biol., 37 (2016) 14321–14328.
 B.-Y. Jin, G.-H. Fu, X. Jiang, H. Pan, D.-K. Zhou, X.-Y. Wei, L. Zhou, L. Chung, S.-S. Zheng, CRABP2 and FABP5 identified by 2D DIGE profiling are upregulated in human bladder cancer, Chin. Med. J. , 126 (2013) 3787–3789.
 A. Gupta, P. Kessler, J. Rawwas, B.R.G. Williams, Regulation of CRABP-II expression by MycN in Wilms tumor, Exp. Cell Res., 314 (2008) 3663–3668.
 A. Gupta, B.R.G. Williams, S.M. Hanash, J. Rawwas, Cellular retinoic acid-binding protein II is a direct transcriptional target of MycN in neuroblastoma, Cancer Res., 66 (2006) 8100–8108.
 W. Xiao, H. Hong, A. Awadallah, S. Yu, L. Zhou, W. Xin, CRABP-II is a highly sensitive and specific diagnostic molecular marker for pancreatic ductal adenocarcinoma in distinguishing from benign pancreatic conditions, Hum. Pathol., 45 (2014) 1177–1183.
 A. Toyama, A. Suzuki, T. Shimada, C. Aoki, Y. Aoki, Y. Umino, Y. Nakamura, D. Aoki, T.-A. Sato, Proteomic characterization of ovarian cancers identifying annexin-A4, phosphoserine aminotransferase, cellular retinoic acid-binding protein 2, and serpin B5 as histology-specific biomarkers, Cancer Sci., 103 (2012) 747–755.
 A.P. Percicote, G.L. Mardegan, E.S. Gugelmim, S.O. Ioshii, A.P. Kuczynski, S. Nagashima, L. de Noronha, Tissue expression of retinoic acid receptor alpha and CRABP2 in metastatic nephroblastomas, Diagn. Pathol., 13 (2018) 9.
 A.H. Cory, T.C. Owen, J.A. Barltrop, J.G. Cory, Use of an aqueous soluble tetrazolium/formazan assay for cell growth assays in culture, Cancer Commun., 3 (1991) 207–212.
 D.L. Crowe, R. Kim, R.A.S. Chandraratna, Retinoic acid differentially regulates cancer cell proliferation via dose-dependent modulation of the mitogen-activated protein kinase pathway, Mol. Cancer Res., 1 (2003) 532–540.
 T.T. Schug, D.C. Berry, N.S. Shaw, S.N. Travis, N. Noy, Opposing effects of retinoic acid on cell growth result from alternate activation of two different nuclear receptors, Cell, 129 (2007) 723–733.
 R.M. Connolly, N.K. Nguyen, S. Sukumar, Molecular pathways: current role and future directions of the retinoic acid pathway in cancer prevention and treatment, Clin. Cancer Res., 19 (2013) 1651–1659.
 J.L. Napoli, Cellular retinoid binding-proteins, CRBP, CRABP, FABP5: Effects on retinoid metabolism, function and related diseases, Pharmacol. Ther., 173 (2017) 19–33.
 B. Weber, H. Hager, B.S. Sorensen, T. McCulloch, A. Mellemgaard, A.A. Khalil, E. Nexo, P. Meldgaard, EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer, Lung Cancer, 83 (2014) 224–230.
 H.A. Yu, M.E. Arcila, M.D. Hellmann, M.G. Kris, M. Ladanyi, G.J. Riely, Poor response to erlotinib in patients with tumors containing baseline EGFR T790M mutations found by routine clinical molecular testing, Ann. Oncol., 25 (2014) 423–428.
 C. Willmore-Payne, J.A. Holden, C.T. Wittwer, L.J. Layfield, The use of EGFR exon 19 and 21 unlabeled DNA probes to screen for activating mutations in non-small cell lung cancer, J. Biomol. Tech., 19 (2008) 217–224.
 M.L. Sos, M. Koker, B.A. Weir, S. Heynck, R. Rabinovsky, T. Zander, J.M. Seeger, J. Weiss, F. Fischer, P. Frommolt, K. Michel, M. Peifer, C. Mermel, L. Girard, M. Peyton, A.F. Gazdar, J.D. Minna, L.A. Garraway, H. Kashkar, W. Pao, et al., PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR, Cancer Res., 69 (2009) 3256–3261.
 M. Prieto-Vila, R.-U. Takahashi, W. Usuba, I. Kohama, T. Ochiya, Drug Resistance Driven by Cancer Stem Cells and Their Niche, Int. J. Mol. Sci., 18 (2017).
 M. Ghosh, H.L. Aguila, J. Michaud, Y. Ai, M.-T. Wu, A. Hemmes, A. Ristimaki, C. Guo, H. Furneaux, T. Hla, Essential role of the RNA-binding protein HuR in progenitor cell survival in mice, J. Clin. Invest., 119 (2009) 3530–3543.
 M. Singh, A.R. Martinez, S. Govindaraju, B.S. Lee, HuR inhibits apoptosis by amplifying Akt signaling through a positive feedback loop, J. Cell. Physiol., 228 (2013) 182–189.
 X. Guan, Cancer metastases: challenges and opportunities, Acta Pharm Sin B, 5 (2015) 402–418.
 G. Spagnol, A.J. Trease, L. Zheng, M. Gutierrez, I. Basu, C. Sarmiento, G. Moore, M. Cervantes, P.L. Sorgen, Connexin43 Carboxyl-Terminal Domain Directly Interacts with β-Catenin, Int. J. Mol. Sci., 19 (2018).
 Z. Ai, A. Fischer, D.C. Spray, A.M. Brown, G.I. Fishman, Wnt-1 regulation of connexin43 in cardiac myocytes, J. Clin. Invest., 105 (2000) 161–171.
 R.P. Huang, M.Z. Hossain, R. Huang, J. Gano, Y. Fan, A.L. Boynton, Connexin 43 (cx43) enhances chemotherapy-induced apoptosis in human glioblastoma cells, Int. J. Cancer, 92 (2001) 130–138.
 H.-T. Xu, Q.-C. Li, Y.-X. Zhang, Y. Zhao, Y. Liu, Z.-Q. Yang, E.-H. Wang, Connexin 43 recruits E-cadherin expression and inhibits the malignant behaviour of lung cancer cells, Folia Histochem. Cytobiol., 46 (2008) 315–321.
 K.C. Alaga, M. Crawford, L. Dagnino, D.W. Laird, Aberrant Cx43 Expression and Mislocalization in Metastatic Human Melanomas, J. Cancer, 8 (2017) 1123–1128.
 L. Kańczuga-Koda, M. Sulkowska, M. Koda, J. Reszeć, W. Famulski, M. Baltaziak, S. Sulkowski, Expression of connexin 43 in breast cancer in comparison with mammary dysplasia and the normal mammary gland, Folia Morphol. , 62 (2003) 439–442.
 Q.-L. Liang, B.-R. Wang, G.-Q. Chen, G.-H. Li, Y.-Y. Xu, Clinical significance of vascular endothelial growth factor and connexin43 for predicting pancreatic cancer clinicopathologic parameters, Med. Oncol., 27 (2010) 1164–1170.
 Zhang Y., Xu H., Wang E., [Expressions of connexin 43 and E-cadherin and their correlation in non-small cell lung cancer], Zhongguo Fei Ai Za Zhi, 8 (2005) 103–106.
 Sun W.-H., Liu H.-M., Li Y.-J., Ji X.-R., Liang D.-P., [A study of the relationship between the expression of connexin43, E-cadherin and biological behaviors of human laryngeal cancer], Zhonghua Er Bi Yan Hou Ke Za Zhi, 39 (2004) 293–297.
 L. Puzzo, R. Caltabiano, R. Parenti, S. Trapasso, E. Allegra, Connexin 43 (Cx43) Expression in Laryngeal Squamous Cell Carcinomas: Preliminary Data on Its Possible Prognostic Role, Head Neck Pathol., 10 (2016) 292–297.
 J.W. Smyth, T.-T. Hong, D. Gao, J.M. Vogan, B.C. Jensen, T.S. Fong, P.C. Simpson, D.Y.R. Stainier, N.C. Chi, R.M. Shaw, Limited forward trafficking of connexin 43 reduces cell-cell coupling in stressed human and mouse myocardium, J. Clin. Invest., 120 (2010) 266–279.
 J.E. Klaunig, L.M. Kamendulis, The role of oxidative stress in carcinogenesis, Annu. Rev. Pharmacol. Toxicol., 44 (2004) 239–267.
 V. Sosa, T. Moliné, R. Somoza, R. Paciucci, H. Kondoh, M.E. LLeonart, Oxidative stress and cancer: an overview, Ageing Res. Rev., 12 (2013) 376–390.
 J. Ming, Y. Zhou, J. Du, S. Fan, B. Pan, Y. Wang, L. Fan, J. Jiang, miR-381 suppresses C/EBPα-dependent Cx43 expression in breast cancer cells, Biosci. Rep., 35 (2015).
 Z.-J. Lin, J. Ming, L. Yang, J.-Z. Du, N. Wang, H.-J. Luo, Mechanism of Regulatory Effect of MicroRNA-206 on Connexin 43 in Distant Metastasis of Breast Cancer, Chin. Med. J. , 129 (2016) 424–434.
 J. Ming, Y. Zhou, J. Du, S. Fan, B. Pan, Y. Wang, L. Fan, J. Jiang, Identification of miR-200a as a novel suppressor of connexin 43 in breast cancer cells, Biosci. Rep., 35 (2015).
 F. Gava, L. Rigal, O. Mondesert, E. Pesce, B. Ducommun, V. Lobjois, Gap junctions contribute to anchorage-independent clustering of breast cancer cells, BMC Cancer, 18 (2018) 221.
 L.A.B. Elias, D.D. Wang, A.R. Kriegstein, Gap junction adhesion is necessary for radial migration in the neocortex, Nature, 448 (2007) 901–907.
 M.E. el-Sabban, B.U. Pauli, Cytoplasmic dye transfer between metastatic tumor cells and vascular endothelium, J. Cell Biol., 115 (1991) 1375–1382.
 A. Zhang, M. Hitomi, N. Bar-Shain, Z. Dalimov, L. Ellis, K.K. Velpula, G.C. Fraizer, R.G. Gourdie, J.D. Lathia, Connexin 43 expression is associated with increased malignancy in prostate cancer cell lines and functions to promote migration, Oncotarget, 6 (2015) 11640–11651.
 J. Behrens, P. Kameritsch, S. Wallner, U. Pohl, K. Pogoda, The carboxyl tail of Cx43 augments p38 mediated cell migration in a gap junction-independent manner, Eur. J. Cell Biol., 89 (2010) 828–838.
 S. Ghosh, A. Kumar, R.P. Tripathi, S. Chandna, Connexin-43 regulates p38-mediated cell migration and invasion induced selectively in tumour cells by low doses of γ-radiation in an ERK-1/2-independent manner, Carcinogenesis, 35 (2014) 383–395.
 A.J. Siller-Jackson, S. Burra, S. Gu, X. Xia, L.F. Bonewald, E. Sprague, J.X. Jiang, Adaptation of connexin 43-hemichannel prostaglandin release to mechanical loading, J. Biol. Chem., 283 (2008) 26374–26382.
 G.M. Yusubalieva, V.P. Baklaushev, O.I. Gurina, Y.A. Zorkina, I.L. Gubskii, G.L. Kobyakov, A.V. Golanov, S.A. Goryainov, G.E. Gorlachev, A.N. Konovalov, A.A. Potapov, V.P. Chekhonin, Treatment of poorly differentiated glioma using a combination of monoclonal antibodies to extracellular connexin-43 fragment, temozolomide, and radiotherapy, Bull. Exp. Biol. Med., 157 (2014) 510–515.
 L. Franco, E. Zocchi, C. Usai, L. Guida, S. Bruzzone, A. Costa, A. De Flora, Paracrine roles of NAD+ and cyclic ADP-ribose in increasing intracellular calcium and enhancing cell proliferation of 3T3 fibroblasts, J. Biol. Chem., 276 (2001) 21642–21648.
 J.M. Rhett, E.S. Yeh, The Potential for Connexin Hemichannels to Drive Breast Cancer Progression through Regulation of the Inflammatory Response, Int. J. Mol. Sci., 19 (2018).
 K.A. Schalper, D. Carvajal-Hausdorf, M.P. Oyarzo, Possible role of hemichannels in cancer, Front. Physiol., 5 (2014) 237.
 Y. Fu, Z.-M. Shao, Q.-Z. He, B.-Q. Jiang, Y. Wu, Z.-G. Zhuang, Hsa-miR-206 represses the proliferation and invasion of breast cancer cells by targeting Cx43, Eur. Rev. Med. Pharmacol. Sci., 19 (2015) 2091–2104.
 Z. Wang, D.-Z. Wang, G.C.T. Pipes, E.N. Olson, Myocardin is a master regulator of smooth muscle gene expression, Proc. Natl. Acad. Sci. U. S. A., 100 (2003) 7129–7134.
 H. Li, Y. Xiang, L.-J. Fan, X.-Y. Zhang, J.-P. Li, C.-X. Yu, L.-Y. Bao, D.-S. Cao, W.-B. Xing, X.-H. Liao, T.-C. Zhang, Myocardin inhibited the gap protein connexin 43 via promoted miR-206 to regulate vascular smooth muscle cell phenotypic switch, Gene, 616 (2017) 22–30.
 B. Davidson, V.M. Abeler, M. Førsund, A. Holth, Y. Yang, Y. Kobayashi, L. Chen, G.B. Kristensen, I.-M. Shih, T.-L. Wang, Gene expression signatures of primary and metastatic uterine leiomyosarcoma, Hum. Pathol., 45 (2014) 691–700.
 D. Ryszawy, M. Sarna, M. Rak, K. Szpak, S. Kędracka-Krok, M. Michalik, M. Siedlar, E. Zuba-Surma, K. Burda, W. Korohoda, Z. Madeja, J. Czyż, Functional links between Snail-1 and Cx43 account for the recruitment of Cx43-positive cells into the invasive front of prostate cancer, Carcinogenesis, 35 (2014) 1920–1930.
 Y. Wang, J. Liu, X. Ying, P.C. Lin, B.P. Zhou, Twist-mediated Epithelial-mesenchymal Transition Promotes Breast Tumor Cell Invasion via Inhibition of Hippo Pathway, Sci. Rep., 6 (2016) 24606.
 Y. Naoi, Y. Miyoshi, T. Taguchi, S.J. Kim, T. Arai, Y. Tamaki, S. Noguchi, Connexin26 expression is associated with lymphatic vessel invasion and poor prognosis in human breast cancer, Breast Cancer Res. Treat., 106 (2007) 11–17.
 K. Ezumi, H. Yamamoto, K. Murata, M. Higashiyama, B. Damdinsuren, Y. Nakamura, N. Kyo, J. Okami, C.Y. Ngan, I. Takemasa, M. Ikeda, M. Sekimoto, N. Matsuura, H. Nojima, M. Monden, Aberrant Expression of Connexin 26 Is Associated with Lung Metastasis of Colorectal Cancer, Clin. Cancer Res., 14 (2008) 677–684.
 Y. Naoi, Y. Miyoshi, T. Taguchi, S.J. Kim, T. Arai, N. Maruyama, Y. Tamaki, S. Noguchi, Connexin26 expression is associated with aggressive phenotype in human papillary and follicular thyroid cancers, Cancer Lett., 262 (2008) 248–256.
 T. Inose, H. Kato, H. Kimura, A. Faried, N. Tanaka, M. Sakai, A. Sano, M. Sohda, M. Nakajima, Y. Fukai, T. Miyazaki, N. Masuda, M. Fukuchi, H. Kuwano, Correlation between connexin 26 expression and poor prognosis of esophageal squamous cell carcinoma, Ann. Surg. Oncol., 16 (2009) 1704–1710.
 J. Yang, G. Qin, M. Luo, J. Chen, Q. Zhang, L. Li, L. Pan, S. Qin, Reciprocal positive regulation between Cx26 and PI3K/Akt pathway confers acquired gefitinib resistance in NSCLC cells via GJIC-independent induction of EMT, Cell Death Dis., 6 (2015) e1829.
 A. Ito, F. Katoh, T.R. Kataoka, M. Okada, N. Tsubota, H. Asada, K. Yoshikawa, S. Maeda, Y. Kitamura, H. Yamasaki, H. Nojima, A role for heterologous gap junctions between melanoma and endothelial cells in metastasis, J. Clin. Invest., 105 (2000) 1189–1197.
 A. Duflot-Dancer, M. Mesnil, H. Yamasaki, Dominant-negative abrogation of connexin-mediated cell growth control by mutant connexin genes, Oncogene, 15 (1997) 2151–2158.
 L. Kanczuga-Koda, M. Sulkowska, M. Koda, R. Rutkowski, S. Sulkowski, Increased expression of gap junction protein--connexin 32 in lymph node metastases of human ductal breast cancer, Folia Histochem. Cytobiol., 45 Suppl 1 (2007) S175–80.
 V. Krutovskikh, G. Mazzoleni, N. Mironov, Y. Omori, A.M. Aguelon, M. Mesnil, F. Berger, C. Partensky, H. Yamasaki, Altered homologous and heterologous gap-junctional intercellular communication in primary human liver tumors associated with aberrant protein localization but not gene mutation of connexin 32, Int. J. Cancer, 56 (1994) 87–94.
 Q. Li, Y. Omori, Y. Nishikawa, T. Yoshioka, Y. Yamamoto, K. Enomoto, Cytoplasmic accumulation of connexin32 protein enhances motility and metastatic ability of human hepatoma cells in vitro and in vivo, Int. J. Cancer, 121 (2007) 536–546.
 J. Yang, B. Liu, Q. Wang, D. Yuan, X. Hong, Y. Yang, L. Tao, Connexin 32 and its derived homotypic gap junctional intercellular communication inhibit the migration and invasion of transfected HeLa cells via enhancement of intercellular adhesion, Mol. Med. Rep., 4 (2011) 971–979.
 Y. Yang, S.-K. Qin, Q. Wu, Z.-S. Wang, R.-S. Zheng, X.-H. Tong, H. Liu, L. Tao, X.-D. He, Connexin-dependent gap junction enhancement is involved in the synergistic effect of sorafenib and all-trans retinoic acid on HCC growth inhibition, Oncol. Rep., 31 (2014) 540–550.
 E. Fujimoto, H. Sato, S. Shirai, Y. Nagashima, K. Fukumoto, H. Hagiwara, E. Negishi, K. Ueno, Y. Omori, H. Yamasaki, K. Hagiwara, T. Yano, Connexin32 as a tumor suppressor gene in a metastatic renal cell carcinoma cell line, Oncogene, 24 (2005) 3684–3690.
 H. Sato, H. Hagiwara, H. Senba, K. Fukumoto, Y. Nagashima, H. Yamasaki, K. Ueno, T. Yano, The inhibitory effect of connexin 32 gene on metastasis in renal cell carcinoma, Mol. Carcinog., 47 (2008) 403–409.
 H. Hagiwara, H. Sato, S. Shirai, S. Kobayashi, K. Fukumoto, T. Ishida, T. Seki, T. Ariga, T. Yano, Connexin 32 down-regulates the fibrinolytic factors in metastatic renal cell carcinoma cells, Life Sci., 78 (2006) 2249–2254.
 Y. Yang, N. Zhang, J. Zhu, X.-T. Hong, H. Liu, Y.-R. Ou, F. Su, R. Wang, Y.-M. Li, Q. Wu, Downregulated connexin32 promotes EMT through the Wnt/β-catenin pathway by targeting Snail expression in hepatocellular carcinoma, Int. J. Oncol., 50 (2017) 1977–1988.
 B. Zhao, W. Zhao, Y. Wang, Y. Xu, J. Xu, K. Tang, S. Zhang, Z. Yin, Q. Wu, X. Wang, Connexin32 regulates hepatoma cell metastasis and proliferation via the p53 and Akt pathways, Oncotarget, 6 (2015) 10116–10133.
 D. Zhang, C. Chen, Y. Li, X. Fu, Y. Xie, Y. Li, Y. Huang, Cx311 acts as a tumour suppressor in non-small cell lung cancer (NSCLC) cell lines through inhibition of cell proliferation and metastasis, J. Cell. Mol. Med., 16 (2012) 1047–1059.
 L. Xu, S.-W. Chen, X.-Y. Qi, X.-X. Li, Y.-B. Sun, Ginsenoside improves papillary thyroid cancer cell malignancies partially through upregulating connexin 31, Kaohsiung J. Med. Sci., 34 (2018) 313–320.
 Jin J., Li C., You J., Zhang B., [miR-610 suppresses lung cancer cell proliferation and invasion by targeting GJA3], Zhonghua Zhong Liu Za Zhi, 36 (2014) 405–411.
 Y.-P. Lin, J.-I. Wu, C.-W. Tseng, H.-J. Chen, L.-H. Wang, Gjb4 serves as a novel biomarker for lung cancer and promotes metastasis and chemoresistance via Src activation, Oncogene, (2018).
 J. Radić, B. Krušlin, M. Šamija, M. Ulamec, M. Milošević, M. Jazvić, I. Šamija, J.J. Grah, A. Bolanča, Z. Kusić, Connexin 43 Expression in Primary Colorectal Carcinomas in Patients with Stage III and IV Disease, Anticancer Res., 36 (2016) 2189–2196.
 X. Zhang, Y. Sun, Z. Wang, Z. Huang, B. Li, J. Fu, Up-regulation of connexin-43 expression in bone marrow mesenchymal stem cells plays a crucial role in adhesion and migration of multiple myeloma cells, Leuk. Lymphoma, 56 (2015) 211–218.
 N.K. Haass, D. Ripperger, E. Wladykowski, P. Dawson, P.A. Gimotty, C. Blome, F. Fischer, P. Schmage, I. Moll, J.M. Brandner, Melanoma progression exhibits a significant impact on connexin expression patterns in the epidermal tumor microenvironment, Histochem. Cell Biol., 133 (2010) 113–124.
 W.C. Sin, Q. Aftab, J.F. Bechberger, J.H. Leung, H. Chen, C.C. Naus, Astrocytes promote glioma invasion via the gap junction protein connexin43, Oncogene, 35 (2016) 1504–1516.
 C. Beck, S. Cayeux, S.D. Lupton, B. Dörken, T. Blankenstein, The thymidine kinase/ganciclovir-mediated “suicide” effect is variable in different tumor cells, Hum. Gene Ther., 6 (1995) 1525–1530.
 T. Jimenez, W.P. Fox, C.C.G. Naus, J. Galipeau, D.J. Belliveau, Connexin over-expression differentially suppresses glioma growth and contributes to the bystander effect following HSV-thymidine kinase gene therapy, Cell Commun. Adhes., 13 (2006) 79–92.
 S. Matono, T. Tanaka, S. Sueyoshi, H. Yamana, H. Fujita, K. Shirouzu, Bystander effect in suicide gene therapy is directly proportional to the degree of gap junctional intercellular communication in esophageal cancer, Int. J. Oncol., 23 (2003) 1309–1315.
 K. Rtibi, D. Grami, S. Selmi, M. Amri, H. Sebai, L. Marzouki, Vinblastine, an anticancer drug, causes constipation and oxidative stress as well as others disruptions in intestinal tract in rat, Toxicol Rep, 4 (2017) 221–225.
 P.H.M. De Mulder, C.M.L. van Herpen, P.A.F. Mulders, Current treatment of renal cell carcinoma, Ann. Oncol., 15 Suppl 4 (2004) iv319–28.
 H. Sato, H. Senba, N. Virgona, K. Fukumoto, T. Ishida, H. Hagiwara, E. Negishi, K. Ueno, H. Yamasaki, T. Yano, Connexin 32 potentiates vinblastine-induced cytotoxicity in renal cell carcinoma cells, Mol. Carcinog., 46 (2007) 215–224.
 H. Sato, K. Fukumoto, S. Hada, H. Hagiwara, E. Fujimoto, E. Negishi, K. Ueno, T. Yano, Enhancing effect of connexin 32 gene on vinorelbine-induced cytotoxicity in A549 lung adenocarcinoma cells, Cancer Chemother. Pharmacol., 60 (2007) 449–457.
 M.C. Piccirillo, G. Daniele, M. Di Maio, J. Bryce, G. De Feo, A. Del Giudice, F. Perrone, A. Morabito, Vinorelbine for non-small cell lung cancer, Expert Opin. Drug Saf., 9 (2010) 493–510.
 R.P. Huang, Y. Fan, M.Z. Hossain, A. Peng, Z.L. Zeng, A.L. Boynton, Reversion of the neoplastic phenotype of human glioblastoma cells by connexin 43 (cx43), Cancer Res., 58 (1998) 5089–5096.
 M. Uzu, H. Sato, R. Yamada, T. Kashiba, Y. Shibata, K. Yamaura, K. Ueno, Effect of enhanced expression of connexin 43 on sunitinib-induced cytotoxicity in mesothelioma cells, J. Pharmacol. Sci., 128 (2015) 17–26.
 D.W. Laird, Connexin phosphorylation as a regulatory event linked to gap junction internalization and degradation, Biochim. Biophys. Acta, 1711 (2005) 172–182.
 J.L. Solan, P.D. Lampe, Connexin phosphorylation as a regulatory event linked to gap junction channel assembly, Biochim. Biophys. Acta, 1711 (2005) 154–163.
 Y. Guo, C. Martinez-Williams, D.E. Rannels, Gap junction-microtubule associations in rat alveolar epithelial cells, Am. J. Physiol. Lung Cell. Mol. Physiol., 285 (2003) L1213–21.
 R.G. Johnson, R.A. Meyer, X.-R. Li, D.M. Preus, L. Tan, H. Grunenwald, A.F. Paulson, D.W. Laird, J.D. Sheridan, Gap junctions assemble in the presence of cytoskeletal inhibitors, but enhanced assembly requires microtubules, Exp. Cell Res., 275 (2002) 67–80.
 P.E. Martin, G. Blundell, S. Ahmad, R.J. Errington, W.H. Evans, Multiple pathways in the trafficking and assembly of connexin 26, 32 and 43 into gap junction intercellular communication channels, J. Cell Sci., 114 (2001) 3845–3855.
 B.N.G. Giepmans, Gap junctions and connexin-interacting proteins, Cardiovasc. Res., 62 (2004) 233–245.
 T. Kojima, N. Sawada, H. Chiba, Y. Kokai, M. Yamamoto, M. Urban, G.H. Lee, E.L. Hertzberg, Y. Mochizuki, D.C. Spray, Induction of tight junctions in human connexin 32 (hCx32)-transfected mouse hepatocytes: connexin 32 interacts with occludin, Biochem. Biophys. Res. Commun., 266 (1999) 222–229.
 T. Kojima, Y. Kokai, H. Chiba, M. Yamamoto, Y. Mochizuki, N. Sawada, Cx32 but not Cx26 is associated with tight junctions in primary cultures of rat hepatocytes, Exp. Cell Res., 263 (2001) 193–201.
 T.A. Martin, W.G. Jiang, Loss of tight junction barrier function and its role in cancer metastasis, Biochim. Biophys. Acta, 1788 (2009) 872–891.
 A. Ito, N. Morita, D. Miura, Y.-I. Koma, T.R. Kataoka, H. Yamasaki, Y. Kitamura, Y. Kita, H. Nojima, A derivative of oleamide potently inhibits the spontaneous metastasis of mouse melanoma BL6 cells, Carcinogenesis, 25 (2004) 2015–2022.
 D. Miura, Y. Kida, H. Nojima, Camellia oil and its distillate fractions effectively inhibit the spontaneous metastasis of mouse melanoma BL6 cells, FEBS Lett., 581 (2007) 2541–2548.
 S. Ferrati, A.K. Gadok, A.D. Brunaugh, C. Zhao, L.A. Heersema, H.D.C. Smyth, J.C. Stachowiak, Connexin membrane materials as potent inhibitors of breast cancer cell migration, J. R. Soc. Interface, 14 (2017).
 G. Charras, E. Paluch, Blebs lead the way: how to migrate without lamellipodia, Nat. Rev. Mol. Cell Biol., 9 (2008) 730.
 P.E.M. Martin, W.H. Evans, Incorporation of connexins into plasma membranes and gap junctions, Cardiovasc. Res., 62 (2004) 378–387.
 A.W. Hunter, R.J. Barker, C. Zhu, R.G. Gourdie, Zonula occludens-1 alters connexin43 gap junction size and organization by influencing channel accretion, Mol. Biol. Cell, 16 (2005) 5686–5698.
 J.M. Rhett, J. Jourdan, R.G. Gourdie, Connexin 43 connexon to gap junction transition is regulated by zonula occludens-1, Mol. Biol. Cell, 22 (2011) 1516–1528.
 G.S. Ghatnekar, C.L. Grek, D.G. Armstrong, S.C. Desai, R.G. Gourdie, The effect of a connexin43-based Peptide on the healing of chronic venous leg ulcers: a multicenter, randomized trial, J. Invest. Dermatol., 135 (2015) 289–298.
 C.L. Grek, J.M. Rhett, J.S. Bruce, M.A. Abt, G.S. Ghatnekar, E.S. Yeh, Targeting connexin 43 with α-connexin carboxyl-terminal (ACT1) peptide enhances the activity of the targeted inhibitors, tamoxifen and lapatinib, in breast cancer: clinical implication for ACT1, BMC Cancer, 15 (2015) 296.
 V.C. Jordan, The role of tamoxifen in the treatment and prevention of breast cancer, Curr. Probl. Cancer, 16 (1992) 129–176.
 D. Bilancia, G. Rosati, A. Dinota, D. Germano, R. Romano, L. Manzione, Lapatinib in breast cancer, Ann. Oncol., 18 Suppl 6 (2007) vi26–30.
 M. Jaraíz-Rodríguez, M.D. Tabernero, M. González-Tablas, A. Otero, A. Orfao, J.M. Medina, A. Tabernero, A Short Region of Connexin43 Reduces Human Glioma Stem Cell Migration, Invasion, and Survival through Src, PTEN, and FAK, Stem Cell Reports, 9 (2017) 451–463.
 B.W. Calder, J. Matthew Rhett, H. Bainbridge, S.A. Fann, R.G. Gourdie, M.J. Yost, Inhibition of connexin 43 hemichannel-mediated ATP release attenuates early inflammation during the foreign body response, Tissue Eng. Part A, 21 (2015) 1752–1762.
 J.M. Rhett, B.W. Calder, S.A. Fann, H. Bainbridge, R.G. Gourdie, M.J. Yost, Mechanism of action of the anti-inflammatory connexin43 mimetic peptide JM2, Am. J. Physiol. Cell Physiol., 313 (2017) C314–C326.
 S.N. Shishido, A. Delahaye, A. Beck, T.A. Nguyen, The anticancer effect of PQ1 in the MMTV-PyVT mouse model, Int. J. Cancer, 134 (2014) 1474–1483.
 C.-F. Tsai, Y.-K. Cheng, D.-Y. Lu, S.-L. Wang, C.-N. Chang, P.-C. Chang, W.-L. Yeh, Inhibition of estrogen receptor reduces connexin 43 expression in breast cancers, Toxicol. Appl. Pharmacol., 338 (2018) 182–190.
 T.N. Zamay, G.S. Zamay, O.S. Kolovskaya, R.A. Zukov, M.M. Petrova, A. Gargaun, M.V. Berezovski, A.S. Kichkailo, Current and Prospective Protein Biomarkers of Lung Cancer, Cancers , 9 (2017).
 N. Okabe, J. Ezaki, T. Yamaura, S. Muto, J. Osugi, H. Tamura, J.-I. Imai, E. Ito, Y. Yanagisawa, R. Honma, M. Gotoh, S. Watanabe, S. Waguri, H. Suzuki, FAM83B is a novel biomarker for diagnosis and prognosis of lung squamous cell carcinoma, Int. J. Oncol., 46 (2015) 999–1006.
 M. Cristofanilli, G.T. Budd, M.J. Ellis, A. Stopeck, J. Matera, M.C. Miller, J.M. Reuben, G.V. Doyle, W.J. Allard, L.W.M.M. Terstappen, D.F. Hayes, Circulating tumor cells, disease progression, and survival in metastatic breast cancer, N. Engl. J. Med., 351 (2004) 781–791.
 M. Uhlén, L. Fagerberg, B.M. Hallström, C. Lindskog, P. Oksvold, A. Mardinoglu, Å. Sivertsson, C. Kampf, E. Sjöstedt, A. Asplund, I. Olsson, K. Edlund, E. Lundberg, S. Navani, C.A.-K. Szigyarto, J. Odeberg, D. Djureinovic, J.O. Takanen, S. Hober, T. Alm, et al., Proteomics Tissue-based map of the human proteome, Science, 347 (2015) 1260419.
 D.J. Kim, W.J. Kim, M. Lim, Y. Hong, S.-J. Lee, S.-H. Hong, J. Heo, H.-Y. Lee, S.-S. Han, Plasma CRABP2 as a Novel Biomarker in Patients with Non-Small Cell Lung Cancer, J. Korean Med. Sci., 33 (2018) e178.
 I. López de Silanes, M. Zhan, A. Lal, X. Yang, M. Gorospe, Identification of a target RNA motif for RNA-binding protein HuR, Proc. Natl. Acad. Sci. U. S. A., 101 (2004) 2987–2992.
 W. Zhang, A.C. Vreeland, N. Noy, RNA-binding protein HuR regulates nuclear import of protein, J. Cell Sci., 129 (2016) 4025–4033.
 F. Milletti, Cell-penetrating peptides: classes, origin, and current landscape, Drug Discov. Today, 17 (2012) 850–860.
 G. Hardavella, R. George, T. Sethi, Lung cancer stem cells-characteristics, phenotype, Transl Lung Cancer Res, 5 (2016) 272–279.